The federal Project Grant award R01HL176882, totaling $734,722.00, was provided by the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) to the University of Alabama at Birmingham (UAB). The award will fund a randomized clinical trial to assess the efficacy of disseminating systolic blood pressure polygenic risk scores (SBP PRS) on SBP control, adherence to a healthy lifestyle, and cardiometabolic profile among 300 hypertensive young and middle-aged U.S....
This federal Project Grant award, totaling $2,158,428 and funded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), supports research aimed at investigating the role of the glycolytic enzyme pyruvate kinase M2 (PKM2) in mediating hypertension and vascular remodeling. The award supports three specific aims: 1) Studying the involvement of PKM2 activation in vascular smooth muscle cells (VSMCs) in hypertension and vascular...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) is funding research to investigate the role of arterial baroreceptors in hypertension. The $136,350 award to the Georgia State University Research Foundation aims to unravel the genetic identity of arterial baroreceptors and link their gene expression to neuronal function during blood pressure regulation. During the initial K99 career...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $1,092,000 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to The Medical College of Wisconsin, Inc. to conduct research on the intersection of the PPARG-RHOBTB1-CULLIN-3 pathway and the renin-angiotensin system, and their role in blood pressure regulation, vascular function, and arterial stiffness. The 7-year project aims to elucidate the molecular and physiological mechanisms controlling vasomotor function, arterial...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $658,885 to the University of Missouri System to investigate the role of the protein Response Gene to Complement 32 (RGC-32) in regulating endothelial-mesenchymal transition (EndoMT) and the development of pulmonary arterial hypertension (PAH). The research aims to determine the molecular mechanisms by which RGC-32 regulates EndoMT in...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $717,236 to The University of Iowa to study the role of neuronal primary cilia in hypertension, autonomic dysfunction, and body fluid imbalance. The goal is to evaluate how conditional ablation of cilia in the supraoptic nucleus affects blood pressure, drinking, urine volume, sodium concentration, plasma osmolality, regional sympathetic...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) will provide $633,720 to The Washington University to conduct research on protein arginylation and its impact on cardiovascular health and development. The key objectives are to: Develop a chemical proteomics platform to comprehensively identify proteins that undergo arginylation in cardiac cells and tissues. This will involve mapping the "arginylome" and...
The federal Project Grant award R01HL177087 was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The $605,678 award supports research to explore a novel mechanism regulating genome-wide mRNA expression in hypoxic lung disease. Specifically, the research aims to investigate how reactive oxygen species generated during hypoxia induce oxidative modifications in DNA regulatory sequences, which recruit enzymes that...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $786,060 to Vanderbilt University Medical Center to study how hypertension induces "trained immunity" in myeloid cells, potentially contributing to chronic inflammation and increased risk of atherosclerotic cardiovascular disease. The research aims to determine how hypertension rewires the epigenome of myeloid progenitors, leading...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $144,362 to the University of Pittsburgh to fund a research project focused on understanding the role of the CYB5R1 enzyme in regulating ferroptosis, an iron-dependent form of cell death, in endothelial cells. The project aims to elucidate the mechanisms by which CYB5R1 protects endothelial cells from ferroptosis, and to determine the...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $2,042,978 to the University of South Alabama to investigate the molecular mechanisms by which the protein progranulin regulates endothelial function and blood pressure control.
The key objectives are to determine how reduced endothelial progranulin levels contribute to the development and progression of hypertension through oxidative stress, AMPK oxidation, and endothelial dysfunction, as well as to examine if the angiotensin-converting enzyme (ACE) degrades endothelial progranulin, leading to endothelial dysfunction and hypertension. This research aims to identify progranulin as a novel regulator of endothelial function and blood pressure. The University of Pittsburgh is a sub-awardee providing expertise on reactive oxygen species and NADPH oxidase experiments.